Preview

PHARMACOECONOMICS. Modern pharmacoeconomics and pharmacoepidemiology

Advanced search

Search


Order results by:     
 
Issue Title
 
Vol 10, No 1 (2017) CLINICAL AND ECONOMIC EVALUATION OF ERIBULIN EFFECTIVENESS IN SOFT TISSUE SARCOMA: RESULTS OF META-ANALYSIS Abstract  similar documents
P. V. Мazin, I. V. Sheshunov, N. K. Mazina, E. M. Markova
"... of adverse events (including haematological) in the trabectedin group was significantly higher than ..."
 
Vol 6, No 2 (2013) FIRST RUSSIAN TYPE 2 DIABETES MELLITUS SIMULATION MODEL WITH DISCREET EVENTS MODELING. HEALTH-ECONOMIC ANALYSIS Abstract  similar documents
A. S. Kolbin, O. K. Khmelnitskiy, A. A. Kurylev, Yu. E. Balykina, M. A. Proskurin, E. P. Kolpak, M. V. Bure
"... complication treatment costs inside the total direct costs, liraglutide monotherapy demonstrated the most long ..."
 
Vol 11, No 3 (2018) Ocrelizumab – a monoclonal antibody – in the treatment of adult patients with multiple sclerosis: a systematic review Abstract  similar documents
D. L. Klabukova, M. E. Holownia-Voloskova, M. V. Davydovskaya, T. N. Ermolaeva, K. I. Polyakova, A. G. Fisun, K. A. Kokushkin
"... . In the ocrelizumab group, the most common adverse events were caused by reactions to the drug infusion ..."
 
Vol 9, No 4 (2016) PHARMACOECONOMIC STUDY OF OLMESARTAN/LERCANIDIPINE AND OFENOPRIL/LERCANIDIPINE COMBINATIONS IN THE TREATMENT OF PATIENTS WITH ESSENTIAL HYPERTENSION Abstract  similar documents
D. S. Kaskaeva, M. M. Petrova, O. V. Zimnitskaya
"... Hg was the smallest in the group zofenopril/lercanidipine. Conclusion. The results ..."
 
Vol 9, No 4 (2016) PHARMACOECONOMIC STUDY OF OLMESARTAN/LERCANIDIPINE AND OFENOPRIL/LERCANIDIPINE COMBINATIONS IN THE TREATMENT OF PATIENTS WITH ESSENTIAL HYPERTENSION Abstract  similar documents
D. S. Kaskaeva, M. M. Petrova, O. V. Zimnitskaya
"... Hg was the smallest in the group zofenopril/lercanidipine. Conclusion. The results ..."
 
Vol 8, No 2 (2015) PHARMACOECONOMIC STUDIES TREATMENT OF PATIENTS WITH INJURIES IN THE DEPARTMENT OF ANESTHESIOLOGY AND RESUSCITATION WITH METHODS ANALYSIS THE COST OF ILLNESS Abstract  similar documents
Anton Alexandrovich Kasatkin
"... The aim of the study was to conduct pharmacoeconomic analysis of treatment of patients with trauma ..."
 
Vol 11, No 3 (2018) Use of medications in children hospitalized with community-acquired pneumonia Abstract  similar documents
D. D. Siukaeva, I. A. Narkevich, V. N. Timchenko, O. D. Nemyatyh, N. A. Maslova
"... .22%). Specifically, the greatest contribution was made by the J01D group «Beta-lactam antibacterial drugs, other» (64 ..."
 
Vol 6, No 2 (2013) COST-EFFECTIVENESS ANALYSIS OVER USE OF TYROSINE KINASE INHIBITORS (TASIGNA AND GLEEVEC) FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE AS FIRST-LINE THERAPY FOR DE NOVO PATIENTS Abstract  similar documents
R. I. Yagudina, A. Yu. Kulikov, I. A. Komarov
"... of this pathology contributes to the improvement of approaches to treatment policy of this group of patients. We ..."
 
Vol 9, No 1 (2016) PHARMACOECONOMIC STUDY OF LENVIMA (LENVATINIB) IN ADVANCED PROGRESSIVE RADIO IODINE REFRACTORY DIFFERENTIATED THYROID CANCER IN THE RUSSIAN FEDERATION Abstract  similar documents
M. Yu. Frolov, V. A. Rogov
"... -effectiveness ratio (CER) and budget impact analysis (BIA) were performed. All calculations were made in the MS ..."
 
Vol 9, No 3 (2016) METHOD «COST-EFFECTIVENESS» IN EVALUETION OF ATIBIOTIC TREATMENT OF ACYTR OBSTRUCTIVE BRONCHITIS IN CHILDREN IN HOSPITAL Abstract  similar documents
O. V. Zhukova, S. V. Kononova
"... (Sintez) was the most effective antibiotic of the cephalosporin group in the treatment of acute ..."
 
Vol 10, No 4 (2017) THE STATE GUARANTEES PROGRAM OF FREE MEDICAL CARE: APPROACHES TO STANDARDIZE THE COSTS OF MEDICAL CARE Abstract  similar documents
Yu. A. Ledovskikh, E. V. Semakova, M. V. Avksent’eva
"... indicates the need for changes to produce new standards that would consider the “completed treatment” factor ..."
 
Vol 7, No 1 (2014) CLINICAL AND PHARMACOECONOMIC ANALYSIS OF CARBAPENEMS (MEROPENEM, IMIPENEM AND DORIPENEM) IN NOSOCOMIAL PNEUMONIA TREATMENT Abstract  similar documents
I. I. Shteynberg, S. K. Zyryanov, Yu. B. Belousov
"... efficacy of carbapenems in nosocomial pneumonia treatment. The study included 87 patients divided into 3 ..."
 
Vol 10, No 3 (2017) Comparative pharmaco-economic analysis of using enzalutamide, abiraterone and cabazitaxel in post-docetaxel castration-resistant prostate cancer patients Abstract  similar documents
N. K. Mazina, P. V. Mazin
"... with other drugs in accordance with the standards, the treatment of adverse events, the end-of-life ..."
 
Vol 6, No 3 (2013) PHARMACOECONOMIC ANALYSIS OF NEUROPROTECTIVE DRUGS IN THE TREATMENT OF ACUTE DISORDERS OF CEREBRAL CIRCULATION Abstract  similar documents
A. Yu. Kulikov, I. Yu. Zinchuk
"... , Cytoflavin with CER175003 RUB has the advantage.It was determined that the preferred scheme of treatment ..."
 
Vol 6, No 4 (2013) Pharmacoeconomical assessment of сerebrolysin in the treatment of the acute disturbances of cerebral circulation Abstract  similar documents
A. Yu. Kulikov, L. A. Komarov
"... of approaches to treatment policy of this group of patients. We performed cost-effectiveness analysis ..."
 
Vol 9, No 1 (2016) PHARMACOECONOMIC SUBSTANTIATION OF APPLICATION OF GENETICALLY ENGINEERED BIOLOGICAL AGENTS IN OUT-PATIENT CONDITIONS Abstract  similar documents
O. Yu. Korennova, L. V. Shukil', S. N. Mal'tsev, I. A. Klinyshkov, N. M. Leganova, E. A. Turusheva, T. V. Kropotina
"... . Adverse events and adverse drug reactions of GEBA were recorded regardless of the conditions of stay ..."
 
Vol 6, No 4 (2013) Pharmacoeconomic analysis of fluid therapy in the treatment of patients with peritonitis Abstract  similar documents
R. I. Yagudina, M. M. Murashko
"... as the effectiveness criterion. The CER amounted to 440,759 roubles for Reamberin, 543,991 roubles for the Ringer ..."
 
Vol 6, No 4 (2013) Pharmacoeconomic analysis of blood glucose meter Contour TS in diabetes treatment Abstract  similar documents
A. U. Kulikov, V. V. Babiy
"... year. Diabetes treatment schemes mostly focused on normalizing the blood glucose level. To achieve ..."
 
Vol 11, No 3 (2018) What is the role of antineoplastic drug safety in reimbursement decision making? Abstract  similar documents
A. S. Kolbin, A. A. Kurylev
"... to reimbursement in Russia has grown from 15% to 28%. This group of drugs is characterized by severe adverse events ..."
 
Vol 6, No 3 (2013) THE ANALYSIS OF THE MARKET OF PHARMACEUTICALS FOR DYSMENORRHEA TREATMENT Abstract  similar documents
N. Yu. Cherkasova, A. V. Fomina, O. V. Filippova
"... The range and sales analysis of pharmaceuticals for the dysmenorrhea treatment on the market ..."
 
Vol 11, No 1 (2018) Pharmacoeconomic assessment of antipsychotic treatment in outpatients with schizophrenia Abstract  similar documents
I. A. Vilyum, B. V. Andreev, M. A. Proskurin, Yu. E. Balykina
"...  and  compared: treatment with classical antipsychotics (CA) and treatment with atypical  antipsychotics (AA ..."
 
Vol 5, No 1 (2012) PHA RMA COE CONOMI CAL EVALUATION OF MULTIPLE MYELOMA TREATMENT WITH REVLIMID (LENALIDOMIDE ) IN THE RUSSIAN FEDE RATION Abstract  similar documents
R. Yagudina, A. Kulikov, B. Misikova
"... Pharmacoeconomic evaluation of treatment of the second and third lines of multiple myeloma ..."
 
Vol 6, No 3 (2013) COST-UTILITY ANALYSIS OVER USE OF TYROSINE KINASE INHIBITORS (TASIGNA AND GLEEVEC) FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE AS FIRST-LINE THERAPY FOR DE NOVO PATIENTS Abstract  similar documents
R. I. Yagudina, A. Yu. Kulikov, I. A. Komarov
"... contributes to the improvement of approaches to treatment policy of this group of patients. We performed cost ..."
 
Vol 7, No 3 (2014) PHARMACOEPIDEMIOLOGY OF ORIGINAL DROTAVERINE USE IN DYSMENORRHEA: RESULTS OF AN INTERNATIONAL MULTICENTER STUDY Abstract  similar documents
A. L. Unanyan, V. A. Alimov, S. E. Arakelov, M. S. Afanasyev, D. V. Baburin, D. V. Blinov, T. D. Guriyev, U. V. Zimovina, A. E. Kadyrova, Yu. M. Kossovich, L. S. Polonskaya
"... adverse events reports were collected. Results: 208 physicians participated and included 5507 patients. 75 ..."
 
Vol 5, No 3 (2012) COST-UTILITY ANALYSIS PATIENTS WITH LOW BACK PAIN AFTER TREATMENT INTRAOSSEOUS BLOCKADES Abstract  similar documents
M. V. Yakovlev, A. U. Kulikov, E. L. Sokov, I. E. Kornilova
"... patients of the second (control group) received a course of conservatively treatment (analgetics, NSAIDs ..."
 
1 - 25 of 142 Items 1 2 3 4 5 6 > >> 

Search tips:

  • Search terms are case-insensitive
  • Common words are ignored
  • By default articles containing any term in the query are returned (i.e., OR is implied)
  • Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
  • Combine multiple words with AND to find articles containing all terms; e.g., education AND research
  • Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
  • Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
  • Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)